2026 Q3 -tulosraportti
18 päivää sitten13,5006 CAD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 9.6. | ||
2026 Q2 -tulosraportti 10.3. | ||
2026 Q1 -tulosraportti 11.12.2025 | ||
2025 Q4 -tulosraportti 15.10.2025 | ||
2025 Q3 -tulosraportti 16.6.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·16.6.New capital raising round! This was 2 weeks ago: https://finance.yahoo.com/sectors/healthcare/articles/briacell-therapeutics-announces-closing-offering-200500340.html " ... offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share." Today's price: $2.83 USD.
·10.4.On March 31, 2026, BriaCell announced that, through its subsidiary BriaPro, it had completed the acquisition of the exclusive global license for Soluble CD80 (sCD80) – a new type of immunotherapy with the potential to change how we treat cancer. This is not just a technical licensing deal – it is a strategic move that could give BriaCell a unique position in next-generation immuno-oncology. What is sCD80 and why is it important? sCD80 is a soluble protein that has shown in preclinical studies the ability to both block tumors' immune-suppressing signals (e.g., PD-L1) and simultaneously activate the body's own T-cells via CD28. This implies a dual mechanism of action – both immune activation and checkpoint blockade – in one and the same molecule. It is an unusual and potentially groundbreaking strategy that could complement or enhance existing treatments such as PD-1/PD-L1 inhibitors. Business implications and competitive advantages BriaCell completed the deal at a low cost – no cash changed hands. Instead, BriaCell received 23.97 million new shares in BriaPro, which increased its ownership stake to 78 %. This means that BriaCell retains the majority of future revenues from sCD80, while minimizing risk by placing development in a separate subsidiary. This is a classic biotech strategy: to ring-fence preclinical assets in a subsidiary to enable external financing, partnerships, or even a future spin-off – without burdening the parent company's balance sheet. It provides flexibility and protects the core business, while retaining control over a potentially valuable asset. Market potential Immunotherapy is one of the hottest areas in oncology, with a global market expected to exceed 200 billion USD within a few years. Most approved immunotherapies focus on blocking immune-suppressing receptors (e.g., PD-1, CTLA-4). sCD80 represents a new point of attack – to restore and enhance the immune system's ability to recognize and fight tumors. Currently, there are no other companies with an sCD80-based therapy in clinical development. This gives BriaCell an opportunity to be first in this niche but potentially very valuable segment. If the technology proves effective in humans, it could open the door for partnerships with larger pharmaceutical companies or even an acquisition. Regulatory opportunities Since sCD80 targets patients who do not respond to existing treatments, there is an opportunity to apply for Orphan Drug Designation or accelerated regulatory pathways (e.g., Fast Track or Breakthrough Therapy Designation) from the FDA and EMA. This can shorten time to market and provide exclusivity, which in turn increases commercial value. Highlights going forward: - Four abstracts on BriaCell's immunotherapies, including sCD80, have been accepted for AACR 2026 – one of the world's most important cancer conferences. This shows that the research is of a high scientific standard and provides increased visibility. - BriaCell has an ongoing Phase III study with Bria-IMT, which is the company's most advanced program. sCD80 could become a future combination partner for Bria-IMT or Bria-OTS+. - With a strong patent portfolio, experienced management, and a clear strategy for managing risk and maximizing value, BriaCell is positioning itself to become an important player in immuno-oncology. Summary The sCD80 deal is a long-term strategic move that strengthens BriaCell's innovative power and future revenue potential. Although the technology is at an early stage, it is precisely such investments that can yield significant returns in biotech – especially when combined with a sound business structure and scientific substance.
27.1.Today’s Phase 2 metastatic breast cancer results. Looks very promissing: https://feeds.issuerdirect.com/news-release.html?newsid=5296111720908342&symbol=BCTX9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations ...which also means that 16 of 25 patients have died. It is very difficult to draw far-reaching conclusions from only 9 surviving patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
18 päivää sitten13,5006 CAD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.6.New capital raising round! This was 2 weeks ago: https://finance.yahoo.com/sectors/healthcare/articles/briacell-therapeutics-announces-closing-offering-200500340.html " ... offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share." Today's price: $2.83 USD.
- ·10.4.On March 31, 2026, BriaCell announced that, through its subsidiary BriaPro, it had completed the acquisition of the exclusive global license for Soluble CD80 (sCD80) – a new type of immunotherapy with the potential to change how we treat cancer. This is not just a technical licensing deal – it is a strategic move that could give BriaCell a unique position in next-generation immuno-oncology. What is sCD80 and why is it important? sCD80 is a soluble protein that has shown in preclinical studies the ability to both block tumors' immune-suppressing signals (e.g., PD-L1) and simultaneously activate the body's own T-cells via CD28. This implies a dual mechanism of action – both immune activation and checkpoint blockade – in one and the same molecule. It is an unusual and potentially groundbreaking strategy that could complement or enhance existing treatments such as PD-1/PD-L1 inhibitors. Business implications and competitive advantages BriaCell completed the deal at a low cost – no cash changed hands. Instead, BriaCell received 23.97 million new shares in BriaPro, which increased its ownership stake to 78 %. This means that BriaCell retains the majority of future revenues from sCD80, while minimizing risk by placing development in a separate subsidiary. This is a classic biotech strategy: to ring-fence preclinical assets in a subsidiary to enable external financing, partnerships, or even a future spin-off – without burdening the parent company's balance sheet. It provides flexibility and protects the core business, while retaining control over a potentially valuable asset. Market potential Immunotherapy is one of the hottest areas in oncology, with a global market expected to exceed 200 billion USD within a few years. Most approved immunotherapies focus on blocking immune-suppressing receptors (e.g., PD-1, CTLA-4). sCD80 represents a new point of attack – to restore and enhance the immune system's ability to recognize and fight tumors. Currently, there are no other companies with an sCD80-based therapy in clinical development. This gives BriaCell an opportunity to be first in this niche but potentially very valuable segment. If the technology proves effective in humans, it could open the door for partnerships with larger pharmaceutical companies or even an acquisition. Regulatory opportunities Since sCD80 targets patients who do not respond to existing treatments, there is an opportunity to apply for Orphan Drug Designation or accelerated regulatory pathways (e.g., Fast Track or Breakthrough Therapy Designation) from the FDA and EMA. This can shorten time to market and provide exclusivity, which in turn increases commercial value. Highlights going forward: - Four abstracts on BriaCell's immunotherapies, including sCD80, have been accepted for AACR 2026 – one of the world's most important cancer conferences. This shows that the research is of a high scientific standard and provides increased visibility. - BriaCell has an ongoing Phase III study with Bria-IMT, which is the company's most advanced program. sCD80 could become a future combination partner for Bria-IMT or Bria-OTS+. - With a strong patent portfolio, experienced management, and a clear strategy for managing risk and maximizing value, BriaCell is positioning itself to become an important player in immuno-oncology. Summary The sCD80 deal is a long-term strategic move that strengthens BriaCell's innovative power and future revenue potential. Although the technology is at an early stage, it is precisely such investments that can yield significant returns in biotech – especially when combined with a sound business structure and scientific substance.
- 27.1.Today’s Phase 2 metastatic breast cancer results. Looks very promissing: https://feeds.issuerdirect.com/news-release.html?newsid=5296111720908342&symbol=BCTX9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations ...which also means that 16 of 25 patients have died. It is very difficult to draw far-reaching conclusions from only 9 surviving patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 9.6. | ||
2026 Q2 -tulosraportti 10.3. | ||
2026 Q1 -tulosraportti 11.12.2025 | ||
2025 Q4 -tulosraportti 15.10.2025 | ||
2025 Q3 -tulosraportti 16.6.2025 |
2026 Q3 -tulosraportti
18 päivää sittenUutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 9.6. | ||
2026 Q2 -tulosraportti 10.3. | ||
2026 Q1 -tulosraportti 11.12.2025 | ||
2025 Q4 -tulosraportti 15.10.2025 | ||
2025 Q3 -tulosraportti 16.6.2025 |
13,5006 CAD/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.6.New capital raising round! This was 2 weeks ago: https://finance.yahoo.com/sectors/healthcare/articles/briacell-therapeutics-announces-closing-offering-200500340.html " ... offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share." Today's price: $2.83 USD.
- ·10.4.On March 31, 2026, BriaCell announced that, through its subsidiary BriaPro, it had completed the acquisition of the exclusive global license for Soluble CD80 (sCD80) – a new type of immunotherapy with the potential to change how we treat cancer. This is not just a technical licensing deal – it is a strategic move that could give BriaCell a unique position in next-generation immuno-oncology. What is sCD80 and why is it important? sCD80 is a soluble protein that has shown in preclinical studies the ability to both block tumors' immune-suppressing signals (e.g., PD-L1) and simultaneously activate the body's own T-cells via CD28. This implies a dual mechanism of action – both immune activation and checkpoint blockade – in one and the same molecule. It is an unusual and potentially groundbreaking strategy that could complement or enhance existing treatments such as PD-1/PD-L1 inhibitors. Business implications and competitive advantages BriaCell completed the deal at a low cost – no cash changed hands. Instead, BriaCell received 23.97 million new shares in BriaPro, which increased its ownership stake to 78 %. This means that BriaCell retains the majority of future revenues from sCD80, while minimizing risk by placing development in a separate subsidiary. This is a classic biotech strategy: to ring-fence preclinical assets in a subsidiary to enable external financing, partnerships, or even a future spin-off – without burdening the parent company's balance sheet. It provides flexibility and protects the core business, while retaining control over a potentially valuable asset. Market potential Immunotherapy is one of the hottest areas in oncology, with a global market expected to exceed 200 billion USD within a few years. Most approved immunotherapies focus on blocking immune-suppressing receptors (e.g., PD-1, CTLA-4). sCD80 represents a new point of attack – to restore and enhance the immune system's ability to recognize and fight tumors. Currently, there are no other companies with an sCD80-based therapy in clinical development. This gives BriaCell an opportunity to be first in this niche but potentially very valuable segment. If the technology proves effective in humans, it could open the door for partnerships with larger pharmaceutical companies or even an acquisition. Regulatory opportunities Since sCD80 targets patients who do not respond to existing treatments, there is an opportunity to apply for Orphan Drug Designation or accelerated regulatory pathways (e.g., Fast Track or Breakthrough Therapy Designation) from the FDA and EMA. This can shorten time to market and provide exclusivity, which in turn increases commercial value. Highlights going forward: - Four abstracts on BriaCell's immunotherapies, including sCD80, have been accepted for AACR 2026 – one of the world's most important cancer conferences. This shows that the research is of a high scientific standard and provides increased visibility. - BriaCell has an ongoing Phase III study with Bria-IMT, which is the company's most advanced program. sCD80 could become a future combination partner for Bria-IMT or Bria-OTS+. - With a strong patent portfolio, experienced management, and a clear strategy for managing risk and maximizing value, BriaCell is positioning itself to become an important player in immuno-oncology. Summary The sCD80 deal is a long-term strategic move that strengthens BriaCell's innovative power and future revenue potential. Although the technology is at an early stage, it is precisely such investments that can yield significant returns in biotech – especially when combined with a sound business structure and scientific substance.
- 27.1.Today’s Phase 2 metastatic breast cancer results. Looks very promissing: https://feeds.issuerdirect.com/news-release.html?newsid=5296111720908342&symbol=BCTX9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations ...which also means that 16 of 25 patients have died. It is very difficult to draw far-reaching conclusions from only 9 surviving patients.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt